Lyell Immunopharma, Inc. Common Stock LYEL
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $40.60 (+163.1% upside)
Key Stats
- Today's Range
- $12.09 – $16.73
- 50-Day Range
- $7.20 – $16.73
- 52-Week Range
- $7.20 – $45.00
- Volume
- 1.10 million shs
- Average Volume
- 183K shs
- Market Cap
- $263.92 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 5.38%
- Days to Cover
- 1.42
About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Related Stocks
Compare head-to-head: LYEL vs LLY·LYEL vs JNJ·LYEL vs ABBV·LYEL vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.